Value for money in drug treatment: economic evaluation of prison methadone

Drug and Alcohol Dependence

Volumn 84, Issue 2, 2006, Pages 160-166

  Warren, Emma ^a   Viney, Rosalie ^a   Shearer, James ^b   Shanahan, Marian ^b   Wodak, Alex ^c   Dolan, Kate ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cost effectiveness; Hepatitis C; Incarceration; Methadone

Indexed keywords

DIAMORPHINE; METHADONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEALTH PROGRAM; HEPATITIS C; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PRISON; SENSITIVITY ANALYSIS; SOCIOECONOMICS; STATISTICAL MODEL;

COSTS AND COST ANALYSIS; HEALTH EXPENDITURES; HEPATITIS C; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; METHADONE; NARCOTICS; NEW SOUTH WALES; PREVALENCE; PRISONS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 33746341842     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.01.010     Document Type: Article

References (33)

1. Anglin M.D., Speckart G.R., Booth M.W., and Ryan T.M. Consequences and costs of shutting off methadone. Addict Behav. 14 (1989) 307-326
2. Barnett P.G., and Hui S.S. The cost-effectiveness of methadone maintenance. Mt Sinai J. Med. 67 (2000) 365-374
3. Belenko, S., Patapis, N., French, M.T., 2005. Economic benefits of drug treatment: a critical review of the evidence for policy makers. Treatment Research Institute, University of Pennsylvania Philadelphia http://www.tresearch.org/resources/specials/2005Feb_EconomicBenefits.pdf, last accessed 20 December, 2004.
4. Bellin E. High dose methadone reduces criminal recidivism in opiate addicts. Addict Res. 7 (1999) 19
5. Caplehorn J.R., Dalton M.S., Cluff M.C., and Petrenas A.M. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 89 (1994) 203-209
6. Catania, H., 2003. Public health needed in prisons. Harm Reduction News: Newsletter of the International Harm Reduction Development Program of the Open Society Institute. 4, 11, 13.
7. Daley M., Love C.T., Shepard D.S., Petersen C.B., White K.L., and Hall F.B. Cost-effectiveness of Connecticut's in-prison substance abuse treatment. J. Offender Rehab. 39 (2004) 69-92
8. Dolan K., Shearer J., Macdonald M., Mattick R.P., Hall W., and Wodak A.D. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol. Depend. 72 (2003) 59-65
9. Dolan K., and Wodak A. The provision of methadone within prison settings. In: Ward J., Mattick R., and Hall W. (Eds). Methadone maintenance treatment and other opioid replacement therapies (1998), Hardwood Academic Publishers, Amsterdam
10. Dolan K.A., Shearer J., White B., Zhou J., Kaldor K., and Wodak A. Four-year follow up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 100 (2005) 820-828
11. Dolan K.A., and Wodak A. An international review of methadone provision in prisons. Addict. Res. 4 (1996) 85-97
12. Doran C., Shanahan M., Mattick R., Ali R., White J., and Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol. Depend. 71 (2003) 295-302
13. French M.T., Zarkin G.A., Hubbard R.L., and Rachal J.V. The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity. Am. J. Drug Alcohol. Abuse. 19 (1993) 19-33
14. Griffith J.D., Hiller M.L., Knight K., and Simpson D.D. A cost-effectiveness analysis of in-prison therapeutic community treatment and risk classification. Prison J. 79 (1999) 352-368
15. Gruer L., and Macleod J. Interruption of methadone treatment by imprisonment [letter]. Br. Med. J. 314 (1997) 1691
16. Hall, W., 1996. Methadone maintenance treatment as a crime control measure. NSW Bureau of Crime Statistics and Research, Crime and Justice Bulletin Number 29.
17. Hall W., Ross J.E., Lynskey M.T., Law M.G., and Degenhardt L.J. How many dependent heroin users are there in Australia?. Med. J. Aust. 173 (2000) 528-531
18. Hall W., Ward J., and Mattick R.P. The effectiveness of methadone maintenance treatment 1: heroin use and crime. In: Ward J., Mattick R.P., and Hall W. (Eds). Methadone maintenance treatment and other opioid replacement therapies (1998), Harwood Academic Publishers, Singapore
19. Harris A.H., Gospodarevskaya E., and Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 23 (2005) 77-91
20. Keen J., Rowse G., Mathers N., Campbell M., and Seivewright N. Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison?. Br. J. Gen. Pract. 50 (2000) 48-49
21. Magura S., Rosenblum A., Lewis C., and Joseph H. The effectiveness of in-jail methadone maintenance. J. Drug Issues 23 (1993) 75-99
22. Martin S.S., Butzin C.A., Saum C.A., and Inciardi J.A. Three-year outcomes of therapeutic community treatment for drug-involved offenders in Delaware: from prison to work release to aftercare. Prison J. 79 (1999) 294-320
23. Masson C.L., Barnett P.G., Sees K.L., Delucchi K.L., Rosen A., Wong W., and Hall S.M. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction 99 (2004) 718-726
24. Mattick, R.P., Digiusto, E., Doran, C., O'Brien, S., Shanahan, M., Kimber, J., Henderson, N., Breen, C., Shearer, J., Gates, J., Shakeshaft, A., And NEPOD Trial Investigators, 2001. National evaluation of pharmacotherapies for opioid dependence: Report of results and recommendations. National Drug and Alcohol Research Centre Sydney.
25. Mccollister K., French M.T., Inciardi J., Butzin C., Martin S., and Hooper R. Post-release substance abuse treatment for criminal offenders: a cost-effectiveness analysis. J. Quant. Criminol. 19 (2003) 389-407
26. Mccollister K., French M.T., Prendergast M., Wexler H., Sacks S., and Hall E. Is in-prison treatment enough? A cost-effectiveness analysis of prison-based treatment and aftercare services for substance abusing offenders. Law Policy 25 (2003) 63-82
27. Mccollister K., French M.T., Prendergast M., Hall E., and Sacks S. Long term cost-effectiveness of addiction treatment for criminal offenders. Justice Quart. 21 (2004) 659-679
28. Metzger D.S., Navaline H., and Woody G.E. Drug abuse treatment as AIDS prevention. Public Health Rep. 113 Suppl. 1 (1998) 97-106
29. Schoenbaum E., Hartel D., Selwyn P., Klein R., Davenny K., Rogers M., Feiner C., and Friedland G. Risk factors for human immunodeficiency virus infection in intravenous drug users. N. Engl. J. Med. 321 (1989) 874-879
30. Shiell A., Briggs A., and Farrell G.C. The cost effectiveness of alpha interferon in the treatment chronic active hepatitis. Med. J. Aust. 160 (1994) 268-272
31. Simpson D.D. The relation of time spent in drug abuse treatment to posttreatment outcome. Am. J. Psychiatry 136 (1979) 1449-1453
32. Warren, E., Viney, R., 2004. An economic evaluation of the prison methadone program in New South Wales, CHERE Project Report no 22. CHERE Sydney (http://www.chere.uts.edu.au/pdf/rep22.pdf, last accessed 20 December 2005).
33. Wexler H.K., Melnick G., Lowe L., and Peters J. Three-year reincarceration outcomes for Amity in-prison therapeutic community and aftercare in California. Prison J. 79 (1999) 321-336